idarucizumab idarucizumab idarucizumab, sold under the brand name praxbind, is a monoclonal antibody used as a reversal agent for dabigatran. idarucizumabmonoclonal antibodytypefab fragmentsourcehumanized (from mouse)targetdabigatranclinical datatrade namespraxbindother namesbi-655075ahfs/drugs.commonographlicense data eu ema: by inn us dailymed: idarucizumab pregnancycategory au: b2 routes ofadministrationintravenousatc codev03ab37 (who) legal statuslegal status au: s4 (prescription only) uk: pom (prescription only) us: ℞-only eu: rx-only identifierscas number1362509-93-0iuphar/bps8298drugbankdb09264chemspidernoneunii97rwb5s1u6keggd10741 ychemical and physical dataformulac2131h3299n555o671s11molar mass47782.71 g·mol−1 idarucizumab was developed by boehringer ingelheim. one study sponsored by the manufacturer found that idarucizumab effectively reversed anticoagulation caused by dabigatran within minutes. it was approved for medical use in the united states and in the european union in 2015. society and culture names idarucizumab is the international nonproprietary name (inn). the description was updated in 2016. idarucizumab is the united states adopted name (usan).